Sakar Healthcare is an integrated pharmaceutical manufacturer transitioning from a diversified CDMO model into a focused, export-led specialty oncology platform. The company operates an EU-GMP approved oncology facility in Bavla and a non-oncology CDMO facility in Changodar, generating revenue through own-brand exports, contract manufacturing, and technology transfer partnerships. Oncology contributed 38% of total revenue in FY26, up from 21% in FY25, with the Bavla facility designed to support INR800 to INR1,000 crores in revenue at optimal utilization over the next 4 to 5 years. The company currently operates at approximately 29% capacity utilization at Bavla, with Q1 FY27 EBITDA margins already expanding to 29% from 27% in FY26, reflecting the high-quality economics of its specialized oncology manufacturing base.
The durability of these economics stems from high entry barriers in cytotoxic oncology manufacturing, specifically the multi-year regulatory qualification cycles and complex facility requirements that restrict new entrants. Sakar has developed 21 oncology APIs in-house, including 16 with written confirmations, and recently secured 2 CEP approvals for Gefitinib and Cytarabine, with 5 more in the pipeline. The company has executed over 65 oncology product contracts and signed its 40th global anti-cancer product agreement with Zydus in Q1 FY27. Because very few manufacturers globally possess integrated API-to-finished-dosage capabilities for oncology, Sakar holds a structural advantage in tech-transfer partnerships, allowing it to command EBITDA margins of 25% to 30% in oncology, with backward-integrated products yielding 35% or higher.
The inflection point is occurring now as Bavla scales from 29% utilization toward 50% to 55% over the next two years, driving significant operating leverage without major incremental capex. By FY28, management targets total oncology revenue of INR280 to INR300 crores, doubling from FY26's INR100 crores, with oncology exports alone reaching INR120 to INR140 crores. Five tech transfer projects are commercializing from Q1 FY27 with partners including Accord, Torrent, and a UK company, representing an initial INR50 to INR100 crore revenue opportunity from the Accord portfolio alone. By the end of the 18 to 24 month window, Sakar aims to cross an INR500 crore total revenue milestone, with a targeted mix of 60% oncology and 40% non-oncology, and an oncology export-to-domestic split of 65% to 35%.
Management has demonstrated consistent execution against its stated milestones across the last four concalls. In November 2025, the company guided to INR280 crores in FY26 revenue and 50% plus growth in FY27, with Bavla utilization just crossing 20%. By May 2026, FY26 revenue guidance was sustained, Bavla utilization reached 29%, and Q4 FY26 EBITDA margin expanded to 37%, validating the operating leverage thesis. The company has successfully commenced commercial supplies to Accord, received 7 site variation approvals across the UK and EU, and doubled its marketing authorizations from 16 to 32 in FY27. Capital allocation remains disciplined, with INR39 crores of capex incurred in 9M FY26 and no major incremental expenditure planned, relying on advance payments from international business to fund working capital.
The quantified earnings path targets 40% revenue growth in FY27 to approximately INR380 crores, with EBITDA margins crossing 30% by end of FY27 as integrated API products scale. For this trajectory to hold, regulatory approval timelines, which average 12 months, must remain on schedule, and the 90 to 150 day lead times for serialization and logistics in initial EU exports must not extend further. The single most important watchpoint is the conversion of the 178 submitted dossiers into commercial revenue, specifically whether partners like Accord and Torrent successfully absorb the initial dispatches to Bulgaria and the UK without operational delays. While gross margins remain healthy at 60% in Q4 FY26, any slippage in EMA approval timelines for the remaining 7 Accord products would directly pressure the targeted doubling of oncology exports in FY28.
companyname: Sakar Healthcare Limited ticker: SAKAR sector: Pharmaceuticals - Oncology-focused Sakar Healthcare is a pharmaceutical manufacturer based in Ahmedabad, Gujarat, founded in 2004 by Mr. Sanjay Shah. It started as a contract manufacturer and has evolved into a vertically integrated company with two distinct businesses: oncology and non-oncology. The company operates two main facilities - the EU GMP approved integrated oncology plant at Bavla and the non-oncology plant at Changodar. In...
Read the full report →regulatory approval, new product segment, geographic expansion
FY27 revenue growth guided at 40% driven by oncology expansion
Guidance maintainedGet valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Sakar Healthcare Limited and 4,900+ companies.
5-day free pass. No card required.